BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carmina E, Lobo RA. Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome? Journal of Women's Health 2018;27:1385-8. [DOI: 10.1089/jwh.2018.7162] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Witchel SF, Teede HJ, Peña AS. Curtailing PCOS. Pediatr Res 2020;87:353-61. [PMID: 31627209 DOI: 10.1038/s41390-019-0615-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
2 Mahboobifard F, Rahmati M, Niknam A, Rojhani E, Momenan AA, Azizi F, Ramezani Tehrani F. Impact of Polycystic Ovary Syndrome on Silent Coronary Artery Disease and Cardiovascular Events; A Long-term Population-based Cohort Study. Arch Med Res 2021:S0188-4409(21)00221-6. [PMID: 34823887 DOI: 10.1016/j.arcmed.2021.11.001] [Reference Citation Analysis]
3 Carmina E, Nasrallah MP, Guastella E, Lobo RA. Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. Clin Endocrinol (Oxf) 2019;91:553-60. [PMID: 31306504 DOI: 10.1111/cen.14063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
4 Shah LM, Wand A, Ying W, Hays AG, Blumenthal RS, Barouch LA, Zakaria S, Sharma G. Prevention Starts in the Womb: Opportunities for Addressing Cardiovascular Risk Factors During Pregnancy and Beyond. Methodist Debakey Cardiovasc J 2021;17:48-59. [PMID: 34824681 DOI: 10.14797/mdcvj.696] [Reference Citation Analysis]
5 Kazemi M, Kim JY, Parry SA, Azziz R, Lujan ME. Disparities in cardio metabolic risk between Black and White women with polycystic ovary syndrome: a systematic review and meta-analysis. Am J Obstet Gynecol 2021;224:428-444.e8. [PMID: 33316275 DOI: 10.1016/j.ajog.2020.12.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Olaniyi KS, Areloegbe SE. Suppression of PCSK9/NF-kB-dependent pathways by acetate ameliorates cardiac inflammation in a rat model of polycystic ovarian syndrome. Life Sci 2022;:120560. [PMID: 35452635 DOI: 10.1016/j.lfs.2022.120560] [Reference Citation Analysis]
7 Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30:399-404. [PMID: 31519403 DOI: 10.1016/j.tcm.2019.08.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
8 Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol 2020;36:12-23. [PMID: 31385729 DOI: 10.1080/09513590.2019.1650337] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]